Introduction
============

Low serum testosterone level have been reported in men with type 2 diabetes mellitus[@b1]--[@b3]. Inverse relationships between the serum testosterone level and cardiovascular risk factors, such as obesity, hypertension, dyslipidemia and insulin resistance, have been observed[@b4]--[@b8]. Recent studies have shown that a low serum testosterone level is strongly associated with an increased likelihood of the metabolic syndrome (MES) in both Caucasian and Asian men[@b9]--[@b11]. In Caucasian and Japanese men, a low serum testosterone level is also related to adverse clinical outcomes including cardiovascular disease (CVD) and premature mortality[@b12]--[@b15]. In 2010, the high prevalence of a low serum testosterone level in patients with type 2 diabetes was addressed in the Endocrine Society\'s Clinical Practice Guideline within the context of testosterone replacement therapy in adult men with androgen deficiency syndrome. The latter was defined by consistent symptoms and signs of androgen deficiency, and an unequivocally low serum testosterone level. The Society recommends measurement of morning serum total testosterone in patients with type 2 diabetes who have symptoms of sexual dysfunction, unexplained weight loss, weakness or mobility limitation[@b16]. Recent interventional trials examining the effect of testosterone replacement on clinical outcomes have mostly been carried out in men with symptomatic androgen deficiency[@b17],[@b18]. To date, the cause of decreased serum testosterone level in patients with type 2 diabetes is not clear. The quest of whether testosterone status should be checked and/or replaced in asymptomatic subjects with type 2 diabetes is ongoing. The aim of the present article was to review the current evidence on low serum testosterone level in patients with type 2 diabetes, and its implications on cardiovascular risk factors, MES and adverse clinical outcomes.

Defining Low Testosterone Level
===============================

Defining the lower limit of normal for serum testosterone level poses a challenge for physicians. First, the threshold serum testosterone level below which adverse clinical outcomes occur in the general population is not known[@b16]. Second, marked variations in the reference ranges of serum testosterone level among laboratories have been reported[@b19]. Furthermore, the reference ranges for testosterone have been derived previously from small convenience samples, or from hospital- or clinic-based patients[@b20]. These approaches are limited by their selection bias, as patients seeking medical care are more likely to have diseases than those in the general population. Therefore, currently, most population-based studies use the serum testosterone level corresponding to the lower limit, quoted from 8.7 to 12.7 nmol/L, of the normal range for young Caucasian men as the threshold[@b16],[@b21], although interethnic differences exist as a result of different mechanisms that will be discussed in the present review.

Serum Total, Free and Protein-Bound Testosterone
------------------------------------------------

Testosterone in men is synthesized and secreted into the circulation almost exclusively by the Leydig cells of the testes. It is mostly bound to plasma proteins. Serum total testosterone is composed of 0.5--3.0% of free testosterone unbound to plasma proteins, 30--44% sex hormone binding globulin (SHBG)-bound testosterone and 54--68% albumin-bound testosterone[@b22],[@b23]. As the binding of testosterone to albumin is non-specific and therefore not tight, the sum of free and albumin-bound testosterone is named bioavailable testosterone, which reflects the hormone available at the cellular level[@b24]. As a significant proportion of circulating serum testosterone level is tightly bound to SHBG, alterations in SHBG concentration might affect total serum testosterone level without altering free or bioavailable testosterone. Conditions that suppress or increase serum SHBG level without affecting circulating free or bioavailable testosterone level are listed in Table[1](#tbl1){ref-type="table"}[@b16]. Researchers tried to examine whether serum total or free testosterone would be a better/more reliable choice when studying the effect of testosterone. The results were mixed. Some reported significant associations of both serum total and free testosterone level with clinical parameters[@b25], whereas others reported that only serum free testosterone[@b26] or only serum total testosterone[@b6] showed significant associations.

###### 

Conditions that suppress or increase serum SHBG level without affecting circulating free or bioavailable testosterone level[@b16]

  ------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Conditions that suppress serum SHBG level   Moderate obesity, type 2 diabetes, nephrotic syndrome, hypothyroidism, acromegaly, familial SHBG deficiency, and use of glucocorticoids, progestins and androgens
  Conditions that increase serum SHBG level   Aging, hepatic cirrhosis, hepatitis, hyperthyroidism, infection with human immunodeficiency virus, and use of anticonvulsants and estrogens
  ------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------

SHBG, sex hormone binding globulin.

Laboratory Assays of Testosterone
---------------------------------

Total testosterone assays are readily available in most laboratories, therefore, serum total testosterone remains the recommended initial measurement in the assessment of testosterone level[@b16]. Serum total testosterone measured using rapid automated immunoassay analyzers are carried out with proprietary reagents that include analogs of testosterone as standards, and reference ranges are provided by the manufacturer of the analyzers. Although these immunoassays are efficient and economical, many of them have limited published validation data, raising questions about the accuracy of these automated methods[@b27]. Furthermore, there is substantial variability in the results from different assays, mostly due to the accreditation of laboratories that are based on the reproducibility of results in comparison with other laboratories using the same kit, rather than on the accuracy of the results[@b21]. Some laboratories now measure serum testosterone level by liquid chromatography tandem mass spectrometry (LC-MS) methods with better accuracy than immunoassays, but are more time-consuming and costly. In fact, the United States Centers for Disease Control and Prevention has initiated a program since 2010 to standardize and harmonize testosterone assays using accuracy-based quality control[@b27].

Epidemiology of Low Serum Testosterone Level
============================================

The prevalence of low serum testosterone level in the general population across different age groups has been examined in several large-scale epidemiological studies. In the Baltimore Longitudinal Study of Aging (BLSA) cohort made up of 3,565 middle-class, mostly Caucasian men from the USA, the incidence of low serum total testosterone increased from approximately 20% of men aged over 60 years, 30% over 70 years, to 50% over 80 years-of-age. A significant, independent and longitudinal effect of age on testosterone has been observed with an average change of −0.124 nmol/L/year in serum total testosterone[@b28]. The same trend has been shown in Europe and Australia[@b29],[@b30].

A similar trend for men with chronic diseases has been shown in the Massachusetts Male Aging Study (MMAS) cohort in which 415 healthy men and 1,294 men with chronic diseases (cancer, coronary heart, hypertension, diabetes and ulcer) from the USA aged 39--70 years were studied. The reduction of total testosterone was 0.4% per year in both groups. The level of total testosterone followed a parallel course in both groups, and subjects with chronic diseases consistently had a 10--15% lower level compared with age-matched healthy subjects[@b31].

In Caucasians, the mean serum total testosterone level for men in large epidemiological studies has been reported to range from 15.1 to 16.6 nmol/L[@b28],[@b29]. In Asians, higher values, ranging from 18.1 to 19.1 nmol/L, were seen in Korea and Japan[@b32],[@b33]. A study on a cohort of Hong Kong (HK) Chinese middle-aged men reported a similar mean serum testosterone level of 17.1 nmol/L in 179 men who had a family history of type 2 diabetes and 17.8 nmol/L in 128 men who had no family history of type 2 diabetes[@b11]. In a more recent study in HK involving a cohort of 1,489 community-dwelling men with a mean age of 72 years, a mean serum total testosterone of 19.0 nmol/L was reported[@b34]. Important geographical and racial differences in the concentrations of serum sex steroids has been reported. Asian men residing in HK and Japan, but not those living in the USA, had 20% higher serum total testosterone than in Caucasians living in the USA, as shown in a large multinational observational prospective cohort of the Osteoporotic Fractures in Men Study. In that study, fasting morning serum samples from these cohorts were sent to a central laboratory in Canada for analysis using the same assay. Group differences in body mass index (BMI) did not explain the geographical differences[@b35]. These differences might be explained by environmental and/or genetic factors influencing the testosterone metabolism[@b36].

Testosterone and Type 2 Diabetes Mellitus
=========================================

Epidemiological Surveys
-----------------------

There is now accumulating evidence that low serum testosterone level is associated with type 2 diabetes with the data summarized in Table[2](#tbl2){ref-type="table"}.

###### 

Epidemiological surveys comparing serum total testosterone levels in men with and without type 2 diabetes

  Source                         Site               Year of publication   Study design                                               No. participants   Age (years)   Findings
  ------------------------------ ------------------ --------------------- ---------------------------------------------------------- ------------------ ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Barrett-Connor *et al*.[@b1]   USA                1992                  Cross-sectional                                            132                53--88        Low serum total testosterone (defined by \< 15.9 nmol/L) was significantly more frequent and lower in men with T2DM (21%, 14.7 ± 5.79 nmol/L) as compared with men without (13%, 17.4 ± 4.74 nmol/L)
  T2DM 44                                                                                                                                                             
  No T2DM 88                                                                                                                                                          
  Oh JY *et al*.[@b124]          USA                2002                  Prospective                                                294                55--89        Odds for new T2DM was 2.7 (95% CI 1.1--6.6) for men in the lowest quartile of total testosterone
  8 years                        Incident T2DM 26                                                                                                                     
  No T2DM 268                                                                                                                                                         
  Ding EL *et al*.[@b2]          Worldwide          2006                  Meta-analysis of cross-sectional and prospective studies   7,100              44--80        Serum total testosterone was significantly lower in men with T2DM in cross-sectional studies (−2.66 nmol/L, 95% CI −3.45 to −1.86) and in prospective studies (−2.48 nmol/L, 95% CI −4.4 to −0.93)
  Cross-sectional T2DM 964                                                                                                                                            
  No T2DM 2,918                                                                                                                                                       
  Prospective T2DM 391                                                                                                                                                
  No T2DM 2,827                                                                                                                                                       
  Cao J *et al*.[@b125]          China              2011                  Cross-sectional                                            492                71--73        Serum total testosterone was significantly lower in subjects with DM (13.8 ± 4.7 nmol/L) than those without (17.1 ± 6.1 nmol/L; *P* \< 0.01)
  T2DM 129                                                                                                                                                            
  No T2DM 363                                                                                                                                                         

CI, confidence interval; DM, diabetes mellitus; T2DM, type 2 diabetes mellitus.

Effects of Testosterone on Body Composition and Intermediary Metabolism
-----------------------------------------------------------------------

There are several mechanisms for the association of low serum testosterone level and type 2 diabetes with insulin resistance and obesity as central features. In experimental studies, androgen receptor knockout mice developed significant insulin resistance rapidly[@b37]. In mouse models, testosterone promoted differentiation of pluripotent stem cells to the myogenic lineage, but inhibited their commitment into adipocytes through an androgen receptor-mediated pathway. These findings explained the well-known effects of testosterone therapy on body composition in men including increment in muscle mass and reduction in fat mass, both of which were expected to decrease insulin resistance[@b38]. In addition to stem cell effects, testosterone decreased insulin resistance by enhancing catecholamine induced lipolysis *in vitro*, and reducing lipoprotein lipase activity and triglyceride uptake in human abdominal tissue *in vivo*[@b39],[@b40]. In both *in vitro* and *in vivo* studies, hypertriglyceridemia led to increased free fatty acids and reduced insulin clearance, which contributed to insulin resistance and hyperinsulinemia (Figure[1](#fig01){ref-type="fig"}). Thus, by promoting lipolysis and myogenesis, testosterone might lead to improved insulin resistance[@b13]. Besides, microarray studies in mice showed that testosterone regulated skeletal muscle genes involved in glucose metabolism that led to decreased systemic insulin resistance[@b41]. In the liver, hepatic androgen receptor signaling inhibited development of insulin resistance in mice[@b42]. This is consistent with the independent and inverse association of testosterone with hepatic steatosis shown in a cross-sectional study carried out in humans[@b43]. Most recently, a higher level of testosterone was shown to independently predict a reduced risk of type 2 diabetes in elderly men[@b44], whereas a lower level was an independent risk factor for high fasting glucose[@b45]. In the Testosterone Replacement in Hypogonadal Men with Either Metabolic Syndrome or Type 2 Diabetes Study, treatment with transdermal testosterone in 136 men with type 2 diabetes improved insulin sensitivity as measured by homeostasis model of assessment-insulin resistance, further supporting the importance of insulin resistance as a mediating factor for the association between low serum testosterone level and type 2 diabetes[@b17]. In short, androgen improves insulin resistance by changing body composition and reducing body fat.

![Dysregulation of the hypothalamic-pituitary-gonadal axis due to genetic-environmental interactions can lead to low testosterone causing changes in body composition resulting in insulin resistance and low grade inflammation to increase cardiovascular risk. This abnormal metabolic milieu can alter level of sex hormone binding globulin to reduce the bioavailability of testosterone. Reduced erythropoiesis due to low testosterone may be associated with activation of cell cycle signaling pathways such as angiotensin II to further increase cardiovascular risk. On the other hand, variability in assay standards can confound the accuracy and interpretation of free and total testosterone level. FSH, follicular stimulating hormone; LH, luteinizing hormone; LHRH, luteinizing-hormone-releasing hormone; TGF-β, transforming growth factor-beta.](jdi0006-0112-f1){#fig01}

Although a low serum testosterone level could contribute to the development of obesity and type 2 diabetes through changes in body composition, obesity might also alter the metabolism of testosterone. In obese men, the peripheral conversion from testosterone to estrogen could attenuate the amplitude of luteinizing hormone pulses and centrally inhibit testosterone production[@b46] to exacerbate the vicious cycle of obesity and low serum testosterone level. Adipose tissue, as an endocrine organ, might regulate Leydig cell function[@b47]. To this end, leptin, an adipokine, has been shown to be inversely correlated with serum testosterone level in men[@b48],[@b49]. In the testes of rodents, Leydig cells expressed leptin receptors and leptin has been shown to inhibit testosterone secretion, suggesting a role of obesity and leptin in the pathogenesis of low testosterone[@b50].

Low testosterone can be perpetuated through defects in the hypothalamic--pituitary--gonadal (HPG) axis. In Caucasian men with type 2 diabetes, 25--40% had hypogonadotropic hypogonadism[@b51]--[@b54]. The normal response to gonadotrophin-releasing hormone of luteinizing hormone suggested the level of the HPG dysfunction exists at the hypothalamus level. Yet, in a small sample consisting of 34 hypogonadal men with diabetes, ten randomly selected patients had magnetic resonance imaging that showed no abnormalities in the hypothalamus or pituitary gland[@b53]. Other researchers suggested that pro-inflammatory factors, such as tumor necrosis factor-α in the testes, could locally inhibit testosterone biosynthesis in Leydig cells[@b47], and testosterone treatment in men was shown to reduce the level of tumor necrosis factor-α[@b55] (Figure[1](#fig01){ref-type="fig"}).

In Japanese men with type 2 diabetes, a negative association between testosterone and glycated albumin-to-hemoglobin A1c (HbA1c) ratio has been reported, possibly through the reduced stimulatory effect of testosterone on erythropoiesis, leading to falsely low HbA1c. This finding has raised the possibility that HbA1c might be underestimated in hypogonadal men with diabetes[@b56].

In brief, multiple lines of evidence from animal experiments, observational studies and randomized controlled trials in humans all appeared to implicate the possible causal role of low serum testosterone level in type 2 diabetes and obesity, although larger-scale randomized clinical studies are required.

Genetic Determinants of Testosterone Metabolism
-----------------------------------------------

Genetic factors, such as racial differences in steroid metabolism, might play a role in explaining the heterogeneity of serum testosterone level and risk associations. In an exploratory analysis of a local clinic-based cohort of Chinese men with type 2 diabetes, 15% of the patients had low serum total testosterone (defined by \< 2.6 ng/mL), which was lower than the prevalence reported in Caucasian men with type 2 diabetes (21--40%; unpublished data), although the differences might be due to geographical, environmental or ethnicity factors[@b1],[@b51]--[@b54]. Another study reported that total testosterone, but not free testosterone or bioavailable testosterone, were lower in young healthy Chinese men than USA men[@b57]. In particular, it was suggested that genetic factors, such as racial differences in steroid metabolism, might play a role. In Asians, a genetic deletion polymorphism of uridine diphosphate-glucuronosyltransferase UGT2B17 was associated with reduced androgen glucuronidation. This resulted in higher level of active androgen in Asians as compared to Caucasians, as Caucasians\' androgen would be glucuronidated into inactive forms faster. Compared with Caucasians, the frequency of this deletion polymorphism of UGT2B17 was 22-fold higher in Asian subjects[@b58]--[@b60]. Other researchers have suggested that environmental, but not genetic, factors influenced serum total testosterone. Here, Chinese men residing in the USA had higher total testosterone than Chinese men living in Beijing, but comparable levels with Caucasians living in the USA[@b61]. In contrast, other studies had shown that Asian men living in HK and Japan, but not those living in the USA, have total testosterone approximately 20% higher than in Caucasian men living in the USA, and this difference was not explained by the group differences in BMI and age[@b35]. The variation within the same ethnic group has been attributed to geographical and environmental influences including diet, environmental chemicals, climate, physical activity and social status[@b62]. In this era of globalization, the interplay between genetic and environmental factors, and their associations with serum testosterone level deserves further investigation, which will throw insight into the pathogenesis, diagnosis and management hypogonadism in different parts of the world for patients with different races and ethnicities.

Testosterone effects are also modified by the genetically determined polymorphism of the androgen receptor (AR) gene[@b63]. The basal and ligand-induced activity of the AR is inversely associated with the length of the CAG repeat chain[@b64]. Significant ethnic differences had been observed in the length of this CAG repeat. The mean length of CAG repeat for Asians, Caucasians and Africans were 22--23, 21--22, and 18--20, respectively[@b64],[@b36]. In the European Male Aging Study, increased estrogen/androgen ratio in association with longer AR CAG repeat was observed[@b29]. Furthermore, a smaller number of AR CAG repeat had been shown to be associated with benign prostate hypertrophy and faster prostate growth during testosterone treatment[@b65],[@b66]. The length of the CAG repeat also varied among individuals of the same ethnic group. In India, men with CAG ≤19 had increased risk of prostate cancer[@b67]. In Caucasians, the odds of having a short CAG repeat (≤17) were substantially higher in patients with lymph node-positive prostate cancer than in those with lymph node-negative disease or in the general population[@b68]. Therefore, assessing the polymorphism at the AR level could be a potential tool towards individualized assessment and treatment of hypogonadism.

Effects of Age on Serum Testosterone Level
------------------------------------------

Aging is well known to result in a decline in sex hormone level, and is likely a combination of testicular and pituitary/hypothalamic defects. In elderly men, there was reduced testicular response to gonadotropins with suppressed and altered pulsatility of the hypothalamic pulse generator[@b69]. In several large cohorts, a significant, independent and longitudinal effect of age on serum total testosterone level had been observed[@b28],[@b30],[@b31],[@b69]. A significant graded inverse association between serum testosterone level and insulin levels independent of age has also been reported in Caucasian men[@b70].

Testosterone and the MES
========================

Low testosterone is commonly associated with a high prevalence of MES[@b71]--[@b73]. MES is a clustering of metabolic risk factors including insulin resistance, hypertension, dyslipidemia and obesity (particularly central adiposity), in part driven by modernization and changing lifestyle. There is now strong epidemiological data supporting the predictive value of MES for further development of type 2 diabetes and/or CVD, although there is ongoing debate whether this is as a result of additive or multiplicative effects of these components. More recent data suggested linkage of this syndrome with other diseases including chronic kidney disease[@b74], non-alcoholic fatty liver disease[@b75], rheumatoid arthritis[@b76] and even cancer[@b77].

Apart from its associations with glycemia and obesity, low serum testosterone level was also associated with high blood pressure[@b78]. In a single-blind randomized study of hypogonadal men with MES and newly diagnosed type 2 diabetes, testosterone treatment reduced blood pressure more effectively than diet and exercise alone[@b79]. In patients who received androgen deprivation therapy with gonadotrophin-releasing hormone-agonists for prostate cancer, there was stiffening of large arteries associated with a drastic decrease in serum testosterone level[@b80]. Testosterone has also been shown to dilate coronary vessels in animals and men, suggesting that it might be an important regulator of vasculature compliance and modifier of blood pressure[@b81]--[@b83].

In the Telecom study, low testosterone was associated with higher total serum cholesterol, triglycerides and low-density lipoprotein cholesterol, and lower high-density lipoprotein cholesterol[@b78]. A similar lipid pattern had been reported in men with profoundly low testosterone secondary to prostate cancer treatment[@b84]. In experimental studies, testosterone had immunomodulating effects with reduced expression of pro-inflammatory cytokines (tumor necrosis factor-α[@b85], interleukin-6 and interleukin-10[@b86]) and increased expression of anti-inflammatory cytokine interleukin-10[@b85],[@b87]. Heufelder *et al*.[@b79] first reported the favorable effects of administration of testosterone on lipid profile in men with MES and newly diagnosed type 2 diabetes. In a subsequent randomized, single-blind, placebo-controlled cross-over study involving 27 Caucasian men (mean age 62 years) with symptomatic testosterone deficiency, testosterone treatment shifted cytokine balance to a state of reduced inflammation and improved lipid profile (Figure[1](#fig01){ref-type="fig"})[@b55].

Laaksonen *et al*.[@b25] reported associations of low serum testosterone level with MES and its components independent of BMI. In the National Health and Nutrition Examination Survey, which involved 1,226 men, serum total testosterone was inversely associated with MES after adjustment for confounders including age, race/ethnicity, use of tobacco and alcohol, physical activity level, low-density lipoprotein cholesterol, C-reactive protein, and insulin resistance as measured by the homeostasis model of assessment-insulin resistance[@b9]. Meta-analysis and systemic reviews quantified that serum total testosterone was 2.17--2.64 nmol/L lower in men with MES when compared with those without[@b72],[@b73]. Three large cross-sectional studies, each involving more than 1,000 men, showed that the inverse association of serum testosterone level with individual components of MES was strongest for central obesity[@b9],[@b71],[@b88].

An important question is whether low testosterone is a cause or consequence of MES. Although most studies showed that changes in serum testosterone level led to changes in body composition, insulin resistance and the presence of MES, the reverse might also be possible. In a prospective observational study that followed 651 middle-aged Finnish men for 11 years, MES predicted a 2.6-fold increased risk of development of low serum testosterone level independent of age, smoking and other potential confounders. The association, although attenuated, remained after adjustment for BMI with an odds ratio of 2.0 (95% confidence interval \[CI\] 1.1--3.8)[@b89]. Other prospective studies have shown that development of MES accelerated the age-related decline in serum testosterone level[@b90],[@b91]. In men with type 2 diabetes, changes in serum testosterone level over time correlated inversely with changes in insulin resistance, raising the possibility that lifestyle and pharmacological management of diabetes that improve insulin resistance might also contribute to increased serum testosterone level. Consistent with this, weight loss by either diet control or bariatric surgery led to a substantial increase in total testosterone, especially in morbidly obese men, and the rise in serum testosterone level was proportional to the amount of weight lost[@b92]--[@b98].

Testosterone, Cardiovascular Disease and Mortality
==================================================

Cardiovascular disease is an important cause of morbidity and mortality in men with type 2 diabetes. In the population-based Osteoporotic Fractures in Men Study cohort from Sweden, men in the highest quartile of serum testosterone level had the lowest risk of cardiovascular events compared with men in the other three quartiles (hazard ratio \[HR\] 0.70, 95% CI 0.56--0.88, *P* = 0.002). When men with known CVD at baseline were excluded, the hazard remained (HR 0.71, 95% CI 0.53--0.95, *P* = 0.029)[@b99]. Similar observations had been reported in Asians. In a prospective cohort of 171 middle-aged Japanese men with coronary risk factors without a previous history of CVD, low serum total testosterone was associated with a significant fourfold higher risk of cardiovascular events when comparing men from the lowest testosterone tertile with those in the highest tertile (*P* \< 0.01), independent of coronary risk factors and endothelial dysfunction[@b14].

Mortality is another outcome affected by serum testosterone level. Shores *et al*. were the first to report that low serum testosterone level, including both serum total and free testosterone, was associated with increased mortality after adjustment for age, medical comorbidity and other clinical covariates in 858 male veterans (HR 1.88, 95% CI 1.34--2.63, *P* \< 0.001)[@b15]. In particular, low serum total testosterone predicted increased risk of cardiovascular mortality with a HR of 1.38 (95% CI 1.02--1.85) in the Bernardo Study[@b100]. A recent systemic review and meta-analysis of 21 studies involving more than 20,000 men living in communities being followed up for a mean duration of 9.7 years concluded that low serum total testosterone increased all-cause (HR 1.35, 95% CI 1.13--1.62, *P* \< 0.001) and cardiovascular mortality (HR 1.25, 95% CI 0.97--1.60, *P* = 0.06)[@b101]. Preliminary results from a Swedish population-based observational study presented at the European Association for the Study of Diabetes 2013 suggested there was an inverse relationship between serum testosterone level and acute myocardial infarction. Diabetic men in the highest quartile of serum total testosterone had a significantly reduced risk of acute MI when compared with those in the lower quartiles, even after adjustment for confounding variables, such as age (HR 0.75, *P* = 0.006). Yet, another recent study that divided a cohort of elderly, community-dwelling subjects into four groups based on their serum testosterone level found that having serum total testosterone level in the middle two quartiles at baseline predicted reduced incidence of death compared with having the highest and lowest levels[@b102], challenging the findings from most of the prior studies that suggested that there was a linear progression for testosterone, with lower level associated with worse clinical outcomes.

In summary, large numbers of epidemiological studies, mainly carried out in Caucasian population, had confirmed the inverse relationship between serum testosterone level and aging, MES, CVD, CVD-related, and all-cause mortality. Besides, men with type 2 diabetes were also more prone to developing low serum testosterone levels, which appeared to be hypothalamic in origin[@b53]. As both type 2 diabetes and low serum testosterone level are predictors for CVD, and given an aging society with 10% of people affected by diabetes in our region, the impacts of low serum testosterone level in a type 2 diabetic population requires further investigation[@b103].

In line with the predictive value of low serum testosterone levels on adverse clinical outcomes, a low serum testosterone level has been shown to be associated with carotid intima-medial thickness independent of BMI, waist-to-hip ratio, hypertension, type 2 diabetes, smoking and serum cholesterol[@b104]. Both animal[@b105] and human studies[@b26],[@b106] showed that a low serum testosterone level was directly linked with factors implicated in atheroma formation. For example, in clinical studies, a low serum testosterone level was associated with inflammation, with elevated C-reactive protein that promoted atheroma formation[@b107]--[@b109]. Similar to its role in lipid profile modification, testosterone shifted the cytokine balance into an anti-inflammatory state, which might prevent or slow the progression of atheromatic plaque and prevent hypercoagulable state[@b55],[@b85]--[@b87]. Testosterone treatment also improved the angina threshold in patients with coronary heart disease by inducing coronary vasodilatation as measured by prolongation in the time to 1-mm ST-segment depression during an exercise tolerance test[@b110],[@b111].

Apart from coronary heart disease, clinical studies had shown that low testosterone level conferred a poor prognosis and higher mortality in men with congestive heart failure[@b112],[@b113]. The presence of testosterone receptors in the myocardium indicated that testosterone might have a direct impact on the cardiac remodeling and renin--angiotensin system contributing to congestive heart failure. Testosterone receptor gene knockout mice showed exacerbation of angiotensin II induced cardiac fibrosis by the enhancement of cardiac transforming growth factor-β gene expression[@b114]. Therefore, a chronic low serum testosterone level state might lead to increased angiotensin II activity and overexpression of transforming growth factor-β with persistent stimulation and differentiation of cardiac fibroblasts to cardiac myofibroblasts (Figure[1](#fig01){ref-type="fig"})[@b115]. Oxidative stress activation could be another explanation for the association between low serum testosterone level and the severity of congestive heart failure. In the rat prostate, testosterone deprivation increased the pro-oxidant capacity by upregulating nicotinamide adenine dinucleotide phosphate hydrogen oxidase, and also decreased the anti-oxidant capacity by reducing reactive oxygen species detoxifying enzymes including manganese superoxide dismutase, peroxiredoxin, and thioredoxin 1[@b116]--[@b119]. Furthermore, in male mice, activation of testosterone receptors was shown to counteract reactive oxygen species damage to the heart induced by doxorubicin[@b120].

Testosterone Replacement Therapy
--------------------------------

Despite these experimental findings, results from interventional trials examining the effect of testosterone replacement on clinical outcomes in symptomatic hypogonadal men remained inconclusive. In the Testosterone Replacement in Hypogonadal Men with Either Metabolic Syndrome or Type 2 Diabetes Study, which involved 220 men with type 2 diabetes and/or MES with symptomatic androgen deficiency randomized to receive either a 60-mg transdermal testosterone gel or placebo once daily over 12 months, testosterone replacement resulted in decreased cardiovascular risk including reduction in insulin resistance as measured by the homeostasis model of assessment-insulin resistance, total cholesterol and low-density lipoprotein cholesterol. Although an improvement in insulin resistance could be expected to result in better glycemic control, the effects of reduction in HbA1c (a secondary outcome) were not shown at the end of the study, as the majority of subjects had controlled type 2 diabetes (HbA1c \<6.5%), and the effect was confounded by the permitted changes in anti-diabetic medications for ethical reasons[@b17]. A larger study with HbA1c as a primary outcome in hypogonadal men with uncontrolled type 2 diabetes is required to investigate this further.

In the Testosterone in Older Men trial, 209 men with low testosterone and self-reported limited mobility were randomized to receive 6-month therapy of either a 100-mg transdermal testosterone gel or placebo once daily with an outcome measure of increased strength and ability to climb stairs. However, the study was prematurely halted by a data and safety monitoring board in 2009, just 3 months after enrollment of the last patient, as a result of increased adverse cardiovascular effects in the treatment group[@b18],[@b121]. Of the 106 patients in the active treatment group, 23 experienced cardiovascular events including myocardial infarction, arrhythmia and elevated blood pressure, compared with just five of the 103 men randomized to the placebo group[@b18]. In 2012, an observational study of a cohort of middle-aged male veterans with low testosterone and comorbidities showed that testosterone treatment was associated with decreased mortality[@b122]. Similarly, a study in Europe that involved replacing testosterone in 64 diabetic men with low testosterone for a mean duration of 41 months found that mortality was reduced with this intervention[@b123]. Contrary to these, in 2013, an observational study with a cohort of veterans, with an average age of 60 years, of which many had underlying cardiovascular disease, who underwent coronary angiography and had a low serum testosterone level reported that the use of testosterone therapy was associated with a 30% increased risk of adverse outcomes including all-cause mortality, MI and ischemic stroke[@b124]. Another observational study reported an increased risk of MI in both older (twofold) and younger men (threefold) with pre-existing heart disease, who were prescribed testosterone therapy within the past 90 days[@b125]. The US Food and Drug Administration had therefore decided to reassess the cardiovascular safety of testosterone therapy since January 2014. To further complicate the issue, post-marketing reports of venous blood clots unrelated to polycythemia in testosterone users had prompted the US Food and Drug Administration to require manufacturers to include a general warning on the drug labeling of all approved testosterone products about the risk of blood clots in the veins in June 2014. A recent meta-analysis that included five randomized controlled trials of 351 men with late onset hypogonadism who were given testosterone replacement/placebo with a mean follow-up time of 6.5 months showed that testosterone reduced fasting plasma glucose, fasting serum insulin and triglyceride levels. However, there was no significant difference for CVD[@b126]. One of the latest contributions to the literature on testosterone and CVD was an analysis of the USA Medicare data, which reported no increased risk of MI with injections of testosterone, and testosterone even appeared to be protective in patients who are at the greatest risk of a cardiovascular event[@b127]. To date, published clinical trials are small, of short duration and often used pharmacological, not physiological, doses of testosterone[@b17],[@b18],[@b79],[@b111]. Given the large number of confounders on serum testosterone level and clinical outcomes, careful phenotyping, large sample size and long follow-up duration will be required to assess the risks and benefits of testosterone replacement therapy.

Conclusion
==========

In conclusion, review of the literature has identified multiple mechanisms supportive of the effects of low serum testosterone level on causing insulin resistance, obesity, vascular dysfunction and inflammation. At this moment, the results from these studies could not support checking testosterone level in asymptomatic men with type 2 diabetes, as an independent predictor effect of low testosterone on adverse clinical outcomes has not been clearly established. Given the high prevalence of type 2 diabetes across the world, future studies with larger cohorts and longer duration of follow up are required to clarify whether low testosterone is merely a reflection of poor cardiovascular risk factors control or is really causing adverse clinical outcomes.
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